One hundred de novo multiple myeloma patients with t(4;14) treated with double intensive therapy according to IFM99 protocols were retrospectively analyzed. The median overall survival (OS) and event-free survival (EFS) were 41.4 and 21 months, respectively, as compared to 65 and 37 for patients included in the IFM99 trials without t(4;14) (Po10
Introduction
Multiple myeloma (MM) is characterized by recurrent chromosomal translocations involving the immunoglobulin heavy-chain locus believed to arise at the time of isotype-class switching. 1 These translocations are detectable in 60% of MM patients by interphase fluorescence in situ hybridization (FISH). 2, 3 One of these recurrent switch translocations is t(4;14)(p16.3;q32.3) identified by FISH in 10-15% of patients with MM 4 which deregulates both FGFR3 and MMSET genes. 5, 6 A small subset of the t(4;14)-positive patients have acquired activating mutations of FGFR3 7 that are able to induce proliferation and to prevent apoptosis. Other reports have suggested that some patients with t(4;14) do not overexpress FGFR3 due to the loss of the derivative chromosome 14, but no difference of survival was observed between FGFR3 expressors and non expressors. 8, 9 Nevertheless, there is currently a wide consensus indicating that t(4;14) is associated with a poor outcome in MM patients treated with either conventional or high-dose therapy (HDT). [7] [8] [9] [10] [11] [12] [13] [14] [15] Primary drug resistance 9, 14 and/or rapid relapse 12, 14 after therapy have been advocated to explain this poor outcome. However, the largest series of de novo t(4;14)-positive patients treated with HDT do not exceed 30 patients [11] [12] [13] [14] [15] and additional data are needed to assess the impact of such a therapy in this subset of patients. Thus, we studied all cases of t(4;14) prospectively treated with double intensive therapy according to IFM99 protocols. One hundred patients with t(4;14) are reported.
Patients and methods

Patients
Between April 2000 and December 2003, 1064 patients under 66 years of age with symptomatic de novo MM were enrolled into three IFM99-02, IFM99-03 and 99-04 therapeutic trials of double intensive therapy that have already been reported. [16] [17] [18] The inclusion of patients in one of these three trials was based on a risk-adapted strategy according to the previously defined prognosis staging system, which used two prognostic factors, initial b 2 -microglobulin level and chromosome 13 deletiondel(13) -by FISH. 19 Patients with both adverse prognostic factors, that is, elevated b 2 -microglobulin (43 mg/l) and del (13) were included in IFM99-03 and 99-04 trials. In both protocols, patients were initially treated with four courses of VAD regimen followed by melphalan (200 mg/m 2 ) (HDM200) plus autologous blood stem cell transplantation (ASCT). When an HLA-sibling donor was available, ASCT was followed by reduced-intensity allogeneic SCT (RIC) according to the IFM9903 protocol. 17 When no donor was available, patients were randomized to receive a second ASCT with melphalan (220 mg/m 2 ) þ /Àanti-IL6 monoclonal antibody according to the IFM99-04 protocol. 18 Patients with either no or only one adverse prognostic factor were included in the IFM99-02 program: VAD þ double ASCT (HDM140 þ HDM200) followed by a randomized three-arm trial of no maintenance treatment vs maintenance treatment with pamidronate vs maintenance treatment with pamidronate and thalidomide. 16 FISH analysis 20 Since del(13) assessment was required for enrolment in the different trials, all patients were primarily analyzed for 13q deletions on highly purified myeloma cells as described previously. 20 This FISH analysis was carried out centrally at the University Hospital of Nantes (H Avet-Loiseau) except for 81 patients whose bone marrow has been analyzed in other laboratories. Among the 983 bone marrow aspirates centrally analyzed, 936 were assessable for del(13) (lack of plasma cells or FISH failures in 47 cases). Other probes were analyzed in the following order: t(11;14), t(4;14), hyperdiploidy, MYC and del(17p). Because of the small number of purified plasma cells in many specimens (median % of plasma cells was 6%), these probes have been tested in 746, 716, 657, 571 and 532 patients, respectively. Translocation t(4;14) was observed in 100 patients/ 716 (14%). The translocation t(4;14) was sought by FISH using a commercially-available probe (Abbott, Chicago, IL, USA). Typically, this 'break-apart' probe usually generates doublesplit, double-fusion images in case of presence of the translocation (green/orange fusions on each derivative chromosome). However, in some cases, only one fusion was observed. These images correspond to the loss of the derivative chromosome 14 as described previously. 8, 9 Consequently, these patients lack FGFR3 expression.
Assessment of response
The response criteria has been defined previously. [16] [17] [18] 20 
Statistical analysis
Overall survival (OS) was calculated from the date of diagnosis to the date of death from any cause. Data on patients who were alive at the time of analysis were censored in the survival analysis on the last date they were known to be alive. Event-free survival (EFS) was calculated from the date of diagnosis to the date of progression, relapse or death. Data on patients who had not shown progression or relapse were censored on the last date they were known to be alive and event-free. Kaplan-Meier curves for OS and EFS were plotted and compared by the use of the log-rank test. Comparison of frequencies between groups were performed using the w 2 test. Prognostic factors for EFS and OS were determined by means of the Cox proportional hazard model for covariate analysis. Usual clinical and biological characteristics at presentation were included in the regression model. To take into account the possible effects of treatment protocols upon prognostic variables, treatment-adjusted statistical analyses were performed. A cutoff date of 15 May 2006 was used for survival analysis. The statistical analyses were performed with the SAS 9.1 software package (SAS Institute Inc., Cary, NC, USA).
Results
Patients' characteristics are listed in Table 1 . At the reference date of 15 May 2006, the median follow-up time for living patients with t(4;14) was 46 months. On an intent-to-treat basis, the median OS for the whole group of patients with t(4;14) was 41.4 months, as compared to 65 months for 616 patients included in the IFM99 trials without t(4;14) (P ¼ 2 Â 10 À8 ), and the estimated 5-year survival was 38.5 vs 64.4% (Figure 1 ). The median EFS for the whole group of patients with t(4;14) was 21 months, as compared to 37 months for patients without t(4;14) (P ¼ 1 Â 10 À12 ), and the estimated 5-year EFS was 7 vs 25% ( Figure 2) . The response rate of the patients with t(4;14) was not different as compared with patients without t(4;14) both after induction therapy and after the completion of the double HDT program (best response ¼ complete response (CR) or very good partial response (VGPR): 19 vs 16%, P ¼ 0.62, and 50 vs 52.4%, P ¼ 0.75, respectively).
In univariate analysis, four factors were associated with adverse outcome for both OS and EFS in the t(4;14)-positive population: initial b 2 -microglobulin X4 mg/l (P ¼ 4 Â 10 À6 and P ¼ 0.01, respectively), initial hemoglobin (Hb) level o10 g/dl (P ¼ 0.001 and P ¼ 0.003, respectively), response to induction Heterogeneity of t(4;14) in multiple myeloma P Moreau et al therapy less than VGPR (P ¼ 0.01 and P ¼ 0.0008, respectively) and best response achieved after HDT less than VGPR (P ¼ 0.001 and P ¼ 1 Â 10
À5
, respectively). International staging system significantly influenced OS (P ¼ 0.002) but not EFS (P ¼ 0.39). Overall survival and EFS were not different between patients expressing (77 patients) or not (23 patients) expressing FGFR3.
Multivariate analysis revealed that two initial parameters, b 2 -microglobulin and Hb level, were statistically independent predictors of both OS (P ¼ 8.10
À5 and P ¼ 0.004, respectively, hazard ratio, 3.33 and 2.33, respectively), and EFS (P ¼ 0.03 and P ¼ 0.004, respectively, hazard ratio, 1.72 and 1.99, respectively), together with best response after HDT (P ¼ 5 Â 10 À6 and P ¼ 0.002, respectively). Analyses according to treatment protocols did not modify the results, these three parameters retain their independent prognostic significance after treatmentadjusted analyses (ASCT/RIC vs others, maintenance vs non maintenance, maintenance vs ASCT/RIC vs no maintenance).
The identification, among this population of 100 cases of t(4;14), of two independent parameters available at diagnosis allowed the determination of a simple staging system able to identify a group of patients with a better prognosis: those presenting at diagnosis with both low b 2 -microglobulin o4 mg/l and high Hb X10 g/l (46% of the patients) had a median OS of 54.6 months, and a median EFS of 26 months, respectively; conversely patients with only one adverse prognostic factor (either high b 2 -microglobulin or low Hb, 39% of the cases) had a median OS and EFS of 37 and 19 months, respectively, and patients with both high b 2 -microglobulin and low Hb (15% of the cases) had a median OS and EFS of 19 and 11 months, respectively (OS, P ¼ 3 Â 10 À5 and EFS, P ¼ 0.0003, log-rank test) (Figures 3 and 4) .
The OS and EFS rates in the subgroup of 46 patients with t(4;14) and favorable initial features (low b 2 -microglobulin o4 mg/l and high Hb X10 g/l) were thus compared to those of the cohort of 300/616 patients included the same three IFM99 trials with identical initial biological characteristics (b 2 -microglobulin o4 mg/l and Hb X10 g/l) but not harboring t(4;14). The median OS in the 'favorable' t(4;14) group of 46 patients was 54.6 months, vs probability of 5-year OS of 73% (P ¼ 0.01, Figure 5 ), and the median EFS was 26 months vs 42.8 (P ¼ 3 Â 10 À6 , Figure 6 ).
Discussion
In most (if not all) series including de novo MM treated with HDT, translocation t(4;14) is clearly associated with an adverse prognostic value. [11] [12] [13] [14] [15] 20 Some authors even suggest that these patients receive minimal benefit from ASCT and could be candidates for novel therapeutic approaches. 12, 13, 21 Our study, the largest one for patients with t(4;14) treated with upfront HDT, allows several comments. The overall response Heterogeneity of t(4;14) in multiple myeloma P Moreau et al rates after both induction and HDT were identical in this subgroup of patients to those achieved in patients without t (4;14) indicating that primary drug resistance may not be the main cause of disease severity. Nevertheless, in the t(4;14) population of patients the magnitude of response is of major importance, since we have demonstrated that the achievement of either CR or VGPR after HDT was a powerful independent prognostic factor. Thus patients only achieving PR (or less) after HDT are at higher risk of early relapse and worse outcome. Moreover, we have shown that the prognosis of t (4;14) is not only related to response but also to initial characteristics, and that this disease is very heterogeneous. This heterogeneity was also recently reported by the Arkansas group in a 70 geneexpression model, this model enabling a clear separation of two groups of t(4;14) patients. 22 The majority of the patients with t(4;14) have an estimated median survival after diagnosis of 18-36 months despite tandem HDT, and among this population new innovative approaches are clearly needed. 21 On the contrary, and that is the major finding of this study, we have identified a subgroup of approximately 45% of the patients with both b 2 -microglobulin o4 mg/l and Hb level X10 g/dl at diagnosis which is experiencing prolonged survival after tandem transplant and benefits from HDT. The median EFS in this subgroup of patients was 27 months, strictly identical to the EFS observed in the intensive arm (single ASCT) of the French IFM90 trial, 23 of the British MRC VII trial 24 or the Italian MMSG97
trial. 25 The median OS of 54.6 months was also impressive, similar to the median OS of the intensive arm of the three trials mentioned above of 57, 54 and 58 months, respectively. Obviously, we cannot conclude that 'good risk' t(4;14) patients appear to have an equivalent outcome to non-t(4;14); t(4;14) by itself in this subset of patients remains an adverse prognostic factor since both OS and EFS of the group of patients presenting with the same initial biological features (low b 2 -microglobulin and high Hb level) treated according to the same protocols with tandem transplant but not harboring t(4;14) are superior. Nevertheless, we report high survival rates in a subset of patients that should not be excluded from HDT trials. Our results could also be explained by the recent availability over our study period of time of novel therapeutic agents at the time of the relapse. Preliminary data suggest that bortezomib 26 or lenalidomide 27 could be the treatment of choice in this situation. New targeted therapies such as FGFR3 inhibitor currently evaluated in prospective protocols could also improve the outcome of this aggressive disease in patients expressing FGFR3. 21, 28 46 vs 300 pts Heterogeneity of t(4;14) in multiple myeloma P Moreau et al
